Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone plus nintedanib safety study in idiopathic pulmonary fibrosis
NL-OMON43469Phase 4Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pirfenidone and nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by Roche. Primary endpoints: Proportion of patients completing 24 weeks of combination treatment, Change from baseline in percent predicted forced vital capacity and 8 more. Started Jun 2016; status: active, not recruiting.
02
Drugs
pirfenidonenintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON43469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43469.